Thesis abstract:

«p»Triple Negative Breast Cancer (TNBC) is the most aggressive subtype of breast cancer with a high rate of metastasis and relapse and a low survival rate. The mainstay treatment is general chemotherapy with low efficacy and severe side effects. Hence, we need effective targeted therapeutics with combined diagnostic features (theranostics) that detect early spread to distal organs. One key approach is to use targeted radionuclide-based theranostics (radiotheranostics). The use of peptides as targeting carriers of radioisotopes can significantly improve the therapeutic outcomes with fewer side effects in cancer patients. Herein, we employ our novel peptide-based targeting strategy to develop the first-in-class peptide-targeted radiotheranostic agent (LPThera) for TNBC therapy. In addition to providing a more effective treatment option than the conventional modalities, with combined diagnostic features, LPThera offers a unique opportunity for fast-growing tumours like TNBC to detect and treat metastatic lesions before they become incurable.«/p»